Alintegimod

N/A

Report date: 2024/06/28 15:24:33
NME

Base Information

Drug NameAlintegimod
Drug Alias Name7HP-3497-HP-3497HP349
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-4/beta-1 activatorsIntegrin alpha-L/beta-2 (LFA-1) activators
TargetsIntegrin alpha-4/beta-1Integrin alpha-L/beta-2 (LFA-1)
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursMismatch Repair Deficient Cancer +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator Companies7 Hills Pharma LLC
China Registration ClassN/A

Develop Information

Active Companies7 Hills Pharma LLC
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursMismatch Repair Deficient Cancer +[16] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A